cyclophosphamide / Generic mfg. - LARVOL DELTA

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. (PubMed, Lancet Haematol) - P2 | "In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active."

Journal • P2 data • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: A randomized controlled trial (ESMO 2025) - "Patients with untreated stage II-III TNBC without access to standard dose pembrolizumab (SDPm) were randomized (1:1) to receive neoadjuvant dose-dense chemotherapy (4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel) with or without 50 mg LDPm administered every 6 weeks for 3 cycles. Conclusions The absolute benefit with LDPm appears numerically comparable to that observed with SDPm in the KN522 trial. Therefore, in resource-constrained settings where SDPm is inaccessible, a low-dose alternative strategy may provide a viable treatment option in patients with TNBC."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma (ASH 2025) - P1, P1/2 | "Here, we report the combined data of these twostudies to provide long term follow up data of GC012F/AZD0120 in NDMM pts.Methods Eligible NDMM pts received a single infusion of GC012F/AZD0120 following two cycles lenalidomide,bortezomib and dexamethasone (RVd) induction therapy...GC012F/AZD0120 was administered at 4 dose levels:1x105/kg (n=1), 1.5x105/kg (n=3), 2x105/kg (n=4), or 3x105/kg (n=22) after a standard 3-daylymphodepletion regimen of fludarabine and cyclophosphamide...3 pts were treated with one dose of tocilizumab and 1 pt was treated with one dose oftocilizumab and corticosteroids...These promising results highlight the potential ofGC012F/AZD0120 CAR-T therapy for treating NDMM patients with HR features and transplant ineligibleNDMM pts. Further research with a larger patient population and extended follow-up is needed tovalidate these findings and address this critically unmet medical need."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Plasmacytoma • PLAAT3

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer (SABCS 2025) - P2 | "Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • CD8 • HER-2 • PGR

First-in-Human Phase 1 Study of RD140, a Fully Human BCMA/GPRC5D Dual-Targeting FasT CAR-T, in Relapsed/Refractory Multiple Myeloma(RRMM) and Plasma Cell Leukemia(PCL) (IMS 2026) - P1 | "Following lymphodepletion with cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m 2 for three consecutive days, RD140 was administered as single infusion at 2 dose levels (DL) of 1x10 5 cells/kg (DL1, n = 3) or 3x10 5 cells/kg (DL2, n=6). The current data demonstrated that BCMA/GPRC5D dual-targeting FasT CAR-T RD140 provide deep responses and a very high MRD negativity rate with a favorable safety profile, including in RRMM pts exposed to anti-CD38, PI and IMiDs. Further evaluation in a larger patient population with longer follow-up is warranted."

CAR T-Cell Therapy • First-in-human • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Double Hit Ultra-High Risk Myeloma Treated with Isa-Vrdc Induction and Isa-Vrd Consolidation: Sub Analysis of the UKMRA RADAR Trial in Newly Diagnosed Transplant Eligible Patients (IMS 2026) - "Introduction: RADAR was designed to evaluate an intensive treatment strategy with Isatuximab-VRD- Cyclophosphamide induction, single autologous stem cell transplantation (ASCT), Isa-VRD consolidation, and Isa-R maintenance in patients with double-hit high-risk disease according to recent consensus IMS/IMWG 2025 high risk criteria (Avet-Loiseau, JCO 2025). High-risk definition in newly diagnosed myeloma continues to evolve as more effective therapies are incorporated into frontline treatment. Within the ultra-high-risk, or “double-hit”, subgroup, the presence of additional characteristics such as R2-ISS Stage IV and High LDH may identify patients with an even greater unmet need. Ongoing analyses of the full 125 patients recruited in HR v4.0 of the RADAR trial will refine these findings."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation

Efficacy and Safety of Daratumumab Plus VCd in Newly Diagnosed Amyloid Light-Chain Amyloidosis with Cardiac Involvement: A Pooled Analysis of Asian Patients from AMY2009 and AMY3001 (IMS 2026) - "Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd) is the only approved frontline regimen for newly diagnosed AL (ND-AL) amyloidosis... D-VCd was observed to show deep and durable hematologic responses alongside clinical benefits and manageable safety profile in Asian patients with cardiac-involved ND-AL amyloidosis, consistent with the findings from the individual AMY2009 and AMY3001 studies. These data support D-VCd as an effective frontline option in this high-risk Asian patient population."

Retrospective data • Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies

Utility of Local Cytogenetic Testing for Risk-Stratified Therapy in Newly Diagnosed Multiple Myeloma: UKMRA RADAR Experience (IMS 2026) - "Patients received induction with VRDc (bortezomib, lenalidomide, dexamethasone and cyclophosphamide), followed by ASCT. Post-ASCT, HR patients were randomised to receive isatuximab or not, alongside VRD/R consolidation/maintenance whilst standard risk (SR) patients receive MRD-guided regimens... RADAR demonstrates that risk-stratified treatment using local laboratories is feasible and quick. The majority of patients were successfully allocated to a risk-adapted treatment pathway following a first CGN test and over 90% in total with a second test. This model is applicable internationally and supports the infrastructure for accessible genetic risk-stratification for all newly diagnosed MM patients."

Hematological Malignancies • Multiple Myeloma • SDC1 • TP53

The Impact of Pomalidomide-Containing Induction on Stem Cell Mobilization and Engraftment in Newly Diagnosed Multiple Myeloma: A Single Center Experience (IMS 2026) - "While lenalidomide-based regimens have been associated with impaired hematopoietic stem cell (HSC) mobilization, clinical data regarding the potential impact of pomalidomide (POM)-containing induction on mobilization outcomes remains extremely limited... This retrospective cohort study analyzed consecutive NDMM patients who underwent HSC mobilization with high-dose cyclophosphamide (HD-CTX) plus pegylated granulocyte colony-stimulating factor (PEG G-CSF) at a single center between January 2023 and December 2025...However, patients in the POM group received a significantly higher number of plerixafor (PXF) doses (p=0.030)... POM-containing induction significantly reduces total CD34+ collection yields and increases PXF requirements. However, it does not preclude the successful harvest of the minimum HSC doses required for transplantation, nor does it compromise post-transplant engraftment. For patients receiving POM-based induction, a risk-adapted mobilization strategy..."

Clinical • Hematological Malignancies • Multiple Myeloma

Real-World ISS-R-ISS Discordance, Extramedullary Disease Biology, and Treatment Patterns in Newly Diagnosed Multiple Myeloma: A North Indian Public Sector Cohort (IMS 2026) - "Of 114 patients, 94 (82.5%) initiated therapy; 89.4% received bortezomib-based regimens: bortezomib-cyclophosphamide-dexamethasone (VCD) 42.6%, bortezomib-lenalidomide-dexamethasone (VRD) 24.5%, VTD 14.9%, VD 7.4%. ISS–R-ISS concordance was fair (kappa=0.268); 68.2% of ISS Stage III patients reclassified to R-ISS Stage II - real-world evidence for mandatory FISH in newly diagnosed MM. EMP’s inverse ISS association (p=0.001) and lower BMPC% support it as a biologically distinct phenotype. Bortezomib-based induction achieved ≥VGPR in 46.8% in a resource-constrained setting."

Clinical • Discordant • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma • Renal Disease

Outcomes of Triple-Class Exposed Relapse/Refractory Multiple Myeloma Patients Treated with Carfilzomib-Based Regimens: Real-World, Single Center Study (IMS 2026) - " This retrospective, single-center cohort study included all consecutive TCE RRMM pts (defined as progressed after proteasome inhibitor [PI], Immunomodulatory agent [IMiD] and daratumumab [DARA]) who received ≥1 dose of K, either with dexamethasone alone (Kd) or in triplet combinations...K regimens included Kd monotherapy (27%), Kd+ cyclophosphamide (KCyd, (30%), Kd+ pomalidomide (KPd, 25%), Kd+DARA (11%), and others (selinexor, lenalidomide, venetoclax)... K-based therapy was safe and effective in TCE RRMM pts. R-ISS score, lower K dose, frailty and prior IMiD refractoriness predict shorter PFS. Combination had no advantage over monotherapy."

Clinical • Real-world • Real-world evidence • CNS Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

Rapid Renal & Hematologic Responses and Favorable Safety With IsaVCd Induction & IsaR Maintenance in NDMM Patients With Severe Renal Impairment: Phase 2 Study Final Results-Greek Myeloma Study Group (IMS 2026) - P2 | "Introduction: Isatuximab(Isa) has shown efficacy and improved renal recovery combined with pomalidomide/dexamethasone (d) in relapsed/refractory (RR) Multiple myeloma (MM). Isa with bortezomib(V), lenalidomide(R), and d (Isa-VRd) is approved for NDMM in both ASCT transplant-eligible (TE) and transplant-ineligible (TI) patients (pts). We evaluated the renal/hematologic efficacy and safety of Isa with V, cyclophosphamide(C), and d (Isa-VCd) followed by Isa and R maintenance in NDMM pts with severe RI EAE116 (NCT05147493) is a phase 2, open-label, multicenter study of NDMM pts with severe RI (eGFR < 30 mL/min/1.73m 2 or requiring dialysis)... IsaVCd induction treatment followed by IsaR maintenance elicits notable renal and hematologic responses and high MRD negativity rates in NDMM pts with severe RI. Responses were rapid, including high dialysis independence rates, with a safety profile consistent with known toxicities. These findings support IsaVCd as a promising..."

Clinical • P2 data • Hematological Malignancies • Multiple Myeloma • Plasmacytoma • Renal Disease

Double Hit Ultra-High Risk Myeloma Treated With Isa-VRD Plus Cyclophosphamide Induction and Isa-VRD Consolidation: QoL Analysis of the UKMRA RADAR Trial in Newly Diagnosed Transplant Eligible Patients (IMS 2026) - "Introduction: RADAR was designed to evaluate an intensive treatment strategy comprising Isatuximab-VRD- Cyclophosphamide induction, single autologous stem cell transplantation (ASCT), Isa-VRD consolidation, and Isa-R maintenance in patients with double-hit high-risk disease. QoL outcomes observed in patients with double hit high risk disease receiving intensified ASCT-based therapy indicate this approach can deliver meaningful improvements in patient reported outcomes. As patients continue prolonged intensive consolidation and maintenance regimen ongoing longitudinal monitoring will assess if these benefits are maintained in the longer term"

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation

Mitigating Cilta-Cel-Associated Delayed Neurotoxicity in Patients With High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide (IMS 2026) - "We previously demonstrated that prophylactic dexamethasone (PPX DEX) administered at ALC hi did not reduce DNT incidence. Single-dose PPX CTX was safe but did not reduce ALC expansion, DNT incidence, or PKS following cilta-cel, but may affect severity of PKS. Our findings support further development of biologically informed, risk-adapted prevention strategies and suggest that refinement of intervention targets may be required."

Clinical • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease • CD4 • CD8

Interim Report of Phase I Results of a Phase I/II, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Elranatamab in Patients With Relapsed AL Amyloidosis (IMS 2026) - " Adult patients with AL amyloidosis who had progressed or were refractory to at least 1 prior line of therapy, inclusive of daratumumab and/or cyclophosphamide/bortezomib/dexamethasone were eligible...Tocilizumab was used in 3 patients, additional steroids used in 2 patients, and supplemental oxygen in 2 patients (37.5%)... Elranatamab demonstrated no new safety signals and rapid, deep and frequent hematological response in patients with relapsed, AL amyloidosis, representing a promising therapeutic option to address this critical unmet need."

Clinical • P1/2 data • Amyloidosis • Hematological Malignancies • Multiple Myeloma

A Novel Analytical Approach to Addressing the Challenge of Assessing Overall Survival in Myeloma Trials in the Context of a Rapidly Evolving Treatment Landscape (IMS 2026) - "Between 2013 and 2016, 1056 patients were randomised between cyclophosphamide, thalidomide, and dexamethasone (CTD), cyclophosphamide, lenalidomide, and dexamethasone (CRD) or carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRD). At trial outset first relapse options included thalidomide, lenalidomide or bortezomib combinations... This work provides a novel application of TSE in order to disentangle the effect of subsequent treatments on OS. In this example, if all patients received subsequent mAB the trial OS difference narrows. This is important for ongoing trials, especially in newly diagnosed populations, as current advances in myeloma therapy to include bispecific antibody therapies at relapse will impact OS treatment effects."

Clinical • Hematological Malignancies • Multiple Myeloma

Mass Spectrometry Identifies Actionable Myeloma Relapse Eight Months Before Electrophoretic Detection (IMS 2026) - "First-line therapy commenced with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (Dara-VCD) in July 2024, achieving a complete serological remission, and subsequently continued on daratumumab maintenance. Had this early relapse been recognised in real time, treatment escalation to a multi-class regimen such as belantamab mafodotin, bortezomib, and dexamethasone (Bela-Vd), or consideration of bispecific or CAR-T therapy (requiring disease control and potentially avoiding bridging therapy), could have been pursued earlier, with the aim of achieving a deeper response before the development of end-organ damage. This case demonstrates that mass spectrometry can detect relapse significantly earlier than conventional electrophoretic methods, providing a clinically meaningful window for earlier intervention at low disease burden. Prospective integration of assays such as EXENT™ GAM into routine monitoring pathways may enable more sensitive disease tracking, inform..."

Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Pain • Orthopedics • B2M

Marrow Immune Features Are Most Informative of Sustained MRD Negative Response in Newly Diagnosed Standard Risk TE Patients: Findings from the UK MRA RADAR Study (IMS 2026) - "SR patients received 4 cycles of bortezomib, lenalidomide, cyclophosphamide and dexamethasone (VRDc) followed by ASCT and MRD test (flow, 10 -5 ) at D100 and 15m post ASCT. MRD-neg patients at D100 receive isatuximab alone, while MRD-pos receive multi-drug consolidation and maintenance... At baseline and pre-treatment, variables indicative of the state of the patient’s own immune system are the most informative of sustained MRD-neg response in SR patients receiving induction and ASCT."

Clinical • IO biomarker • Minimal residual disease • B2M • B3GAT1 • CCR7 • CD27 • CD8 • GZMB • KLRG1 • SDC1

Long-Term Follow-Up of Busulfan Plus Cyclophosphamide and Etoposide Versus High-Dose Melphalan as Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (IMS 2026) - " A total of 35 patients with multiple myeloma, enrolled between March 2016 and September 2021, patients aged 47-67 (median 57 years) with multiple myeloma were enrolled to receive bortezomib, thalidomide and dexamethasone (VTD) induction followed by ASCT. Our study showed that BuCyE is an effective and well-tolerated alternative to HDMEL conditioning, with good PFS."

Hematological Malignancies • Multiple Myeloma • Transplantation

Intermediate Dose of Arac as Safe and Effective Savage Therapy for Multiple Myeloma Poor Mobilizers (IMS 2026) - "Granulocyte-colony stimulating factor (G-CSF) with or without cyclophosphamide (Cy) and on demand plerixafor is currently a standard regimen for HSCs mobilization in MM patients, but the HSC collection success rate is still less than 100% (Mina R et al, Haematologica , 2024). We can therefore conclude that, even if in our limited number of poor mobilizers, mobilization with intermediate dose of Ara-C+G-CSF and plerixafor was adequate in all patients and it could be considered an effective and safe savage mobilizing strategy."

Hematological Malignancies • Infectious Disease • Multiple Myeloma • CD34

Immunomodulatory Salvage Reverses Primary Refractoriness to Bispecific T-Cell Engagers in Multiple Myeloma (IMS 2026) - " We report five patients (pts) with RRMM treated between 2023 and 2026 in three tertiary cancer centers who were primarily refractory or have shown progressive disease after at least one full cycle of teclistamab (n=2) or talquetamab (n=3). All 5 pts received immunomodulatory salvage with pomalidomide (POM) added to ongoing TCE therapy (POM mono, n=2) or initiated shortly after TCE discontinuation (daratumumab(DARA)-POM-cyclophosphamide(CY)-dexamethasone(dex), n=1; POM-CY-dex, n=1; elotuzumab-POM-dex, n=1)... Response depth and kinetics exceeded what is expected from used salvage regimens alone. Persistent TCE concentrations after discontinuation together with POM-based salvage led to a de facto combination therapy. This combination was able to reverse functional TCE resistance, even in pts refractory to the salvage drugs."

Bispecific • Immunomodulating • Hematological Malignancies • Multiple Myeloma • CD38 • CD4 • CD8 • IKZF1 • IKZF3 • IL2 • TIGIT

Immune Determinants of MRD Response in Ultra-High-Risk Multiple Myeloma: Analysis from the UK MRA RADAR Study (IMS 2026) - "In protocol v4, they received 4 cycles of isatuximab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Isa-VRDc) followed by ASCT and a further 4 cycles of Isa-VRD then IsaR maintenance. Distinct immune mechanisms may underpin response depth at different treatment stages, with early response to CD38 therapy linked to innate immunity, and later ASCT responses increasingly shaped by adaptive T-cell immunity."

Hematological Malignancies • Multiple Myeloma • B3GAT1 • CD27 • CD4 • CD8 • GZMB • KLRC1 • NCAM1

Health-Related Quality of Life (Hrqol) Is Influenced by Clinical Features Rather Than Genetic Risk in Newly Diagnosed Myeloma Patients: Results from the UK Myeloma Research Alliance (MRA) RADAR Trial (IMS 2026) - "Induction, consolidation and maintenance therapies use combinations of lenalidomide, cyclophosphamide, bortezomib, dexamethasone and isatuximab. HRQoL of NDMM patients is largely influenced by clinical features. Patients diagnosed based on SLiM criteria have better HRQoL but similar emotional functioning compared to those with CRAB features. NDMM have worse HRQoL than SMM patients."

Clinical • HEOR • Anorexia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Insomnia • Multiple Myeloma • Pulmonary Disease • Sleep Disorder

Design of the Phase 2 ALANIS Study: Belantamab Mafodotin in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (Vcd) in Patients with Newly Diagnosed Amyloid Light Chain Amyloidosis (IMS 2026) - P2 | "The ALANIS trial will determine the role of belamaf in the newly diagnosed AL amyloidosis treatment landscape, where new therapies providing deep responses are needed. Funding: GSK. Drug linker technology licensed from Seagen Inc.; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa."

Clinical • Combination therapy • P2 data • Amyloidosis • Cardiovascular • Hematological Disorders • Ophthalmology • Renal Disease

Chemo-Free Mobilization with Upfront Plerixafor Improves Efficiency and Reduces Procedural Burden in Multiple Myeloma (IMS 2026) - "In the era of novel induction therapies, particularly lenalidomide and anti-CD38 monoclonal antibodies, impaired mobilization has become increasingly recognized, highlighting the need for optimized strategies in routine clinical practice...Patients received either upfront plerixafor plus G-CSF (PLE group, n=98) or cyclophosphamide plus G-CSF (CY group, n=122)... In this large real-world cohort, upfront plerixafor provided superior mobilization efficiency with reduced toxicity and procedural burden compared with chemotherapy-based strategies, without compromising transplant outcomes. These findings support a shift toward chemo-free mobilization approaches and suggest potential benefits in healthcare resource utilization, particularly in the context of modern induction therapies. This pragmatic strategy may have broad applicability across diverse clinical settings."

Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • CD34